DSM, CRUCELL SIGN LICENSE AGREEMENT WITH FERRING ON PER.C6 VACCINE TECHNOLOGY

Crucell said it and its PER.C6 technology contract manufacturer DSM Biologics signed a commercial licensing agreement with Ferring Pharmaceutical. The deal allows Ferring to use the PER.C6 cell line in the production of a specific therapeutic protein in the women's healthcare sector. The agreement is the second of its kind with Ferring, a Scandinavia-based biopharmaceutical company.

Forbes (http://www.forbes.com/home/feeds/afx/2005/12/21/afx2406528.html)